Abstract
Erectile dysfunction (ED) is the main and most frequent side effect after radical prostatectomy. Also, ED is the primary impact factor for quality of life after radical prostatectomy. ED post radical prostatectomy is mainly due to lesions in the neurovascular bundles which can occur by partial or total sectioning, by stretching (the most common), or by thermal lesion of the nervous fibers, leading to a condition called “neuropraxia”. The term penile rehabilitation (PR) after prostatectomy has been defined as any intervention with the intent of reestablishing preoperative erectile function and includes the isolated or combined use of phosphodiesterase 5 inhibitors (PDE5i), intracavernous injection, vacuum erectile device therapy, and use of intraurethral drugs. The use of intracavernous drugs, of intraurethral prostaglandin and the use of vacuum therapy have a poorly defined role regarding postoperative penile rehabilitation and must be better investigated through further studies. The use of PDE5i as PR is strongly supported by experimental research, but most clinical trials found controversial results.
Keywords: Erectile dysfunction, penis erection, prostatectomy, penile function, phosphodiesterase type 5 inhibitors, prostate cancer, rehabilitation.
Current Drug Targets
Title:Penile Rehabilitation After Radical Prostatectomy
Volume: 16 Issue: 5
Author(s): David Jacques Cohen and Sidney Glina
Affiliation:
Keywords: Erectile dysfunction, penis erection, prostatectomy, penile function, phosphodiesterase type 5 inhibitors, prostate cancer, rehabilitation.
Abstract: Erectile dysfunction (ED) is the main and most frequent side effect after radical prostatectomy. Also, ED is the primary impact factor for quality of life after radical prostatectomy. ED post radical prostatectomy is mainly due to lesions in the neurovascular bundles which can occur by partial or total sectioning, by stretching (the most common), or by thermal lesion of the nervous fibers, leading to a condition called “neuropraxia”. The term penile rehabilitation (PR) after prostatectomy has been defined as any intervention with the intent of reestablishing preoperative erectile function and includes the isolated or combined use of phosphodiesterase 5 inhibitors (PDE5i), intracavernous injection, vacuum erectile device therapy, and use of intraurethral drugs. The use of intracavernous drugs, of intraurethral prostaglandin and the use of vacuum therapy have a poorly defined role regarding postoperative penile rehabilitation and must be better investigated through further studies. The use of PDE5i as PR is strongly supported by experimental research, but most clinical trials found controversial results.
Export Options
About this article
Cite this article as:
Cohen Jacques David and Glina Sidney, Penile Rehabilitation After Radical Prostatectomy, Current Drug Targets 2015; 16 (5) . https://dx.doi.org/10.2174/1389450116666150202153832
DOI https://dx.doi.org/10.2174/1389450116666150202153832 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytochemicals and Cancer Stem Cells: A Pancreatic Cancer Overview
Current Chemical Biology The Early Bird Catches the Worm – Can Evolution Teach us Lessons in Fighting HIV?
Current HIV Research Can the Use of HIV-1 Derived Gene Transfer Vectors for Clinical Application be Justified?
Current Gene Therapy Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology Current Role of Proteomics in Pancreatic Cancer Biomarkers Research
Current Proteomics Older and New Formulations of Cladribine. Pharmacology and Clinical Efficacy in Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Pharmacokinetics and Pharmacodynamics of Lipidic Nano-Particles in Cancer
Anti-Cancer Agents in Medicinal Chemistry Applications of Aptamers in Targeted Imaging: State of the Art
Current Topics in Medicinal Chemistry Dietary Phytochemicals in Chemoprevention of Cancer
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Genotoxicity of Different Nanocarriers: Possible Modifications for the Delivery of Nucleic Acids
Current Drug Discovery Technologies Production and Application of Copper Radiopharmaceuticals
Current Radiopharmaceuticals The Role of DNA-Microarray in Translational Cancer Research
Current Pharmacogenomics Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design Overview of the Metallometabolomic Methodology for Metal-Based Drug Metabolism
Current Drug Metabolism Anti-CD20 Antibody in Primary Sjogren's Syndrome Managemen
Current Pharmaceutical Biotechnology The Management of Thymoma - A Review of the Status Quo with Practical Treatment Recommendations
Current Respiratory Medicine Reviews Bioinformatics Approach to BDNF and BDNF-Related Disorders
Current Neuropharmacology Function of miRNA in Controlling Drug Resistance of Human Cancers
Current Drug Targets Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers
Current Drug Targets Molecular Imaging and Targeted Drug Delivery Using Albumin-Based Nanoparticles
Current Pharmaceutical Design